Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Abstract
Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker of AR-targeted therapy resistance in castration-resistant prostate cancer (CRPC), but its importance in CSPC remains understudied.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 10, 2022
- Source ID
- 10.1158/1078-0432.ccr-22-0851
Entities
People
- Adam G Sowalsky
- Adam Sharp
- Amanda Swain
- Anson Ku
- Antje Neeb
- Bora Gurel
- Cynthia T. Sprenger
- Daniel Nava Rodrigues
- Denisa Bogdan
- Eva Corey
- Fatima Karzai
- Ilsa M. Coleman
- Ines Figueiredo
- Johann de Bono
- John R. Bright
- Jonathan Welti
- Joshua W. Russo
- Juan M. Jimenez-vacas
- Lawrence D. True
- Michael C. Haffner
- Nichelle C. Whitlock
- Peter S Nelson
- Radhika A. Patel
- Rosina T Lis
- Ruth Riisnaes
- Scott Wilkinson
- Shana Y. Trostel
- Stephen R Plymate
- Steven P Balk
- William L. Dahut
- Yuan Wei
Organizations
- Congressionally Directed Medical Research Programs
- Department of Health and Social Care
- Doris Duke Charitable Foundation
- National Institutes of Health
- Prostate Cancer Foundation
- Prostate Cancer UK
- V Foundation for Cancer Research
- Wellcome